Organization
Massachusetts General Hospital, Harvard Medical School
3 abstracts
Abstract
A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC).Org: H. Lee Moffitt Cancer Center and Research Institute, Washington University School of Medicine, University of Washington School of Medicine, Massachusetts General Hospital, Harvard Medical School, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center,
Abstract
Exploratory biomarker analysis of acelERA breast cancer (BC): Phase II study of giredestrant vs. physician’s choice of endocrine therapy (PCET) for previously treated, estrogen receptor-positive, HER2-negative advanced BC (ER+, HER2– aBC).Org: Genentech, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Massachusetts General Hospital, Harvard Medical School, Garvan Institute of Medical Research, St Vincent's Clinical School, University of New South Wales, F. Hoffmann-La Roche Ltd,
Abstract
Importance of clinical decision making in precision oncology: Discordance in recommendation between next generation sequencing test vendor and molecular tumour board in India.Org: BALCO Medical Center, Ernakulam Medical Centre and MOSC Medical College, MVR Cancer Center and Research Institute, Amrita Institute of Medical Sciences, Mediclinic City Hospital,